Publication date: Jun 23, 2025
Patients with systemic rheumatic diseases were initially excluded from coronavirus disease 2019 (COVID-19) vaccine trials. Real-world data on vaccine safety in this population remain limited, particularly for non-mRNA vaccines. The aim of this study was to evaluate the safety of COVID-19 vaccines in patients with rheumatic diseases and/or psoriasis. A longitudinal observational study including vaccinated patients ≥18 years old with rheumatic diseases and/or psoriasis vaccinated against COVID-19 was conducted. Adverse events (AEs) and disease flares were documented. Multivariable logistic regression analysis identified factors associated with AEs. Among 2160 patients with rheumatic diseases and/or psoriasis vaccinated against COVID-19 (3988 doses), 29. 6% reported at least 1 AE, mostly mild/moderate flu-like symptoms and local hypersensitivity. AE incidence was highest for mRNA-1273 (316. 7/1000 doses) and lowest for BBIBP-CorV (95. 4/1000). Heterologous regimens and ChAdOx1 nCoV-19 as first dose were associated with increased AE risk, whereas BBIBP-CorV showed the opposite effect. Disease flares occurred in 2. 5% of patients, predominantly arthritis and arthralgia, without association with any specific vaccines. COVID-19 vaccines were generally well tolerated, with AE rates comparable to the general population. Heterologous regimens and vector-based and mRNA vaccines had higher AE incidence. These findings provide valuable safety data on vaccines used in Argentina and the region.
| Concepts | Keywords |
|---|---|
| Argentina | COVID-19 vaccines |
| Arthritis | psoriasis |
| Coronavirus | rheumatic diseases |
| Mild | |
| Vaccinated |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Rheumatic Diseases |
| disease | MESH | Psoriasis |
| disease | MESH | coronavirus disease 2019 |
| disease | MESH | hypersensitivity |
| disease | MESH | arthritis |
| disease | MESH | arthralgia |
| disease | MESH | Long Covid |